Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers

Sleep

Volumn 30, Issue 9, 2007, Pages 1145-1152

  Haack, Monika ^a,b   Sanchez, Elsa ^a   Mullington, Janet M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Fatigue; IL 6; Inflammation; Pain; Prostaglandin; Sleep deprivation; TNF receptor p55

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; AUTACOID; C REACTIVE PROTEIN; INTERLEUKIN 6; PROSTAGLANDIN D2; PROSTAGLANDIN E2; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR P55; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE EXACERBATION; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MALE; NORMAL HUMAN; PAIN; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SLEEP DEPRIVATION; SLEEP TIME; UNITED STATES; URINALYSIS; VOLUNTEER;

EID: 34548514172     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/30.9.1145     Document Type: Article

References (52)

1. Benca RM, Okawa M, Uchiyama M, et al. Sleep and mood disorders. Sleep Med Rev 1997;1:45-56.
2. Jason LA, Richman JA, Rademaker AW, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med 1999;159:2129-37.
3. Menefee LA, Cohen MJ, Anderson WR, Doghramji K, Frank ED, Lee H. Sleep disturbance and nonmalignant chronic pain: a comprehensive review of the literature. Pain Med 2000;1:156-72.
4. Bloom BJ, Owens JA, McGuinn M, Nobile C, Schaeffer L, Alario AJ. Sleep and its relationship to pain, dysfunction, and disease activity in juvenile rheumatoid arthritis. J Rheumatol 2002;29:169-73.
5. Raymond I, Ancoli-Israel S, Choiniere M. Sleep disturbances, pain and analgesia in adults hospitalized for burn injuries. Sleep Med 2004;5:551-9.
6. Cooperman NR, Mullin FJ, Kleitman N. Studies on the physiology of sleep. XI. Further observations on the effects of prolonged sleeplessness. Am J Physiol 1934;107:589-93.
7. Kundermann B, Spernal J, Huber MT, Krieg JC, Lautenbacher S. Sleep deprivation affects thermal pain thresholds but not somatosensory thresholds in healthy volunteers. Psychosom Med 2004;66:932-7.
8. Onen SH, Alloui A, Gross A, Eschallier A, Dubray C. The effects of total sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects. J Sleep Res 2001;10:35-42.
9. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculosketal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 1975;37:341-51.
10. Haack M, Mullington JM. Sustained sleep restriction reduces emotional and physical well-being. Pain 2005;119:56-64.
11. Smith MT, Edwards RR, McCann UD, Haythornthwaite JA. The effects of sleep deprivation on pain inhibition and spontaneous pain in women. Sleep 2007;30:494-505.
12. Moldofsky H, Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 1976;38:35-44.
13. Older SA, Battafarano DF, Danning CL, et al. The effects of delta wave sleep interruption on pain thresholds and fibromyalgia-like symptoms in healthy subjects; correlations with insulin-like growth factor I. J Rheumatol 1998;25:1180-6.
14. Lentz MJ, Landis CA, Rothermel J, Shaver JL. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol 1999;26:1586-92.
15. Shearer WT, Reuben JM, Mullington JM, et al. Soluble TNF-α receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol 2001;107:165-70.
16. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231-40.
17. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 1999;84:2603-7.
18. Meier-Ewert HK, Ridker PM, Rifai N, et al.Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 2004;43:678-83.
19. Vgontzas AN, Zoumakis E, Bixler EO, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 2004;89:2119-26.
20. Vgontzas AN, Zoumakis M, Papanicolaou DA, et al. Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism 2002;51:887-92.
21. Burgos I, Richter L, Klein T, et al. Increased nocturnal interleukin-6 excretion in patients with primary insomnia: a pilot study. Brain Behav Immun 2006;20:246-53.
22. Griffith R. Prostaglandins and inflammation. In: Gallin J, Synderman R, editors. Inflammation: basic principles and clinical correlates. Philadelphia: Lippincott Williams and Wilkins; 1999:349-60.
23. 2, are correlated with increasing propensity towards sleep in rats. Brain Res 1997;751:81-9.
24. Song C, Lin AH, Bonaccorso S, et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 1998;49:211-9.
25. Jordan W, Tumani H, Cohrs S, et al. Narcolepsy - Increased L-PGDS (beta-trace) levels correlate with excessive daytime sleepiness but not with cataplexy. J Neurol 2005; 252:1372-8.
26. McMahon SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp Neurol 2005;192:444-62.
27. Haack M, Kraus T, Schuld A, Dalal M, Koethe D, Pollmächer T. Diurnal variations of interleukin-6 plasma levels are confounded by blood drawing procedures. Psychoneuroendocrinology 2002;27:921-31.
28. Cohen J. Statistical power analysis for the behavioral sciences. Revised edition. New York: Academic Press; 1977.
29. Poole S, Woolf CJ. Cytokine-nerve growth facor interactions in inflammatory hyperalgesia. In: Watkins LR, Maier SF, eds. Cytokines and pain. Basel: Birkhäuser; 1999: 89-132.
30. McMahon SB, Bennett DLH, Bevan S. Inflammatory mediators and modulators of pain. In: McMahon SB, Koltzenburg M, eds. Textbook of pain. London: Elsevier, 2005.
31. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
32. Vollmer-Conna U, Fazou C, Cameron B, et al. Production of proinflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med 2004;34:1289-97.
33. Maihöfner C, Handwerker HO, Neundorfer B, Birklein F. Mechanical hyperalgesia in complex regional pain syndrome: a role for TNF-alpha? Neurology 2005;65:311-3.
34. Reyes-Gibby CC, Mendoza TR, Wang S, Anderson KO, Cleeland CS. Pain and fatigue in community-dwelling adults. Pain Med 2003;4:231-7.
35. Korth C, Mullington J, Schreiber W, Pollmächer T. Influence of endotoxin on daytime sleep in humans. Infect Immun 1996;64:1110-5.
36. Hermann DM, Mullington J, Hinze-Selch D, Schreiber W, Galanos C, Pollmacher T. Endotoxin-induced changes in sleep and sleepiness during the day. Psychoneuroendocrinology 1998;23:427-37.
37. Krueger JM, Majde JA. Humoral links between sleep and the immune system: research issues. Ann N Y Acad Sci 2003;992:9-20.
38. Pollmächer T, Haack M, Schuld A, Reichenberg A, Yirmiya R. Low levels of circulating inflammatory cytokines - Do they affect human brain functions? Brain Behav Immun 2002;16:525-32.
39. Fotherby MD, Critchley D, Potter JF. Effect of hospitalization on conventional and 24-hour blood pressure. Age Ageing 1995;24:25-9.
40. Broussard J, Haack M, Serrador J, Mullington J. Effects of sleep restriction on blood pressure. Sleep 2004;27(Suppl):A171.
41. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
42. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413-8.
43. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
44. Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals 2005;14:166-74.
45. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999;461:25-46.
46. Alesci S, Martinez PE, Kelkar S, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 2005;90:2522-30.
47. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60:39-47.
48. Motivala SJ, Sarfatti A, Olmos L, Irwin MR. Inflammatory markers and sleep disturbance in major depression. Psychosom Med 2005;67:187-94.
49. Hayaishi O, Urade Y. Prostaglandin D2 in sleep-wake regulation: recent progress and perspectives. Neuroscientist 2002;8:12-5.
50. Jordan W, Tumani H, Cohrs S, et al. Prostaglandin D synthase (beta-trace) in healthy human sleep. Sleep 2004;27:867-74.
51. Scholz H. Prostaglandins. Am J Physiol Regul Integr Comp Physiol 2003;285:R512-4.
52. Frölich JC, Wilson TW, Sweetman BJ, et al. Urinary prostaglandins. Identification and origin. J Clin Invest 1975;55:763-70.